Episode Overview

For the second time in two decades, a phase 3 trial has shown a statistically significant improvement over R-CHOP in newly diagnosed diffuse large B-cell lymphoma (DLBCL). In this episode, Eddie, Raj, and Ashwin sit down with Professor Charles Herbaux to unpack the data, debate the clinical implications, and ask the question that's on every hematologist's mind: is this enough to change practice?

Background: Setting the Stage for Tafasitamab

Before diving into frontMIND, the episode provides context on tafasitamab, a CD19-targeting monoclonal antibody

L-MIND (Phase 2 — relapsed/refractory DLBCL):

• 81 patients with R/R DLBCL
• ORR 58%, complete response rate 41%
• Established activity of tafasitamab + lenalidomide in the relapsed setting
• https://pubmed.ncbi.nlm.nih.gov/32511983/

First-MIND (Phase 1b — frontline DLBCL, IPI 2–5):

• 66 patients randomized: tafa-R-CHOP (n=33) vs. tafa-len-R-CHOP (n=33)
• ORR: 75.8% vs. 81.8%, respectively
• Serious treatment-emergent adverse events: 42.4% vs. 51.5%
• Provided the signal (and the safety caution) to move to phase 3
• https://pubmed.ncbi.nlm.nih.gov/37369099/

The frontMIND Trial

Design: Phase 3, double-blind, placebo-controlled randomized trial

• Intervention: R-CHOP + tafasitamab (12 mg/kg IV days 1, 8, 15 per cycle) + lenalidomide (25 mg/day, days 1–10 per cycle)
• Control: R-CHOP + placebos
• GCSF mandatory (given double-blind design); VTE prophylaxis (heparin or aspirin) mandatory given lenalidomide
• Enrollment: May 2021 – March 2023; 899 patients randomized
• Primary endpoint: Investigator-assessed progression-free survival (PFS)

Patient Population:

• Age 18–80; DLBCL or high-grade B-cell lymphoma, IPI 3–5
• Median age: 65 years
• 96% advanced stage; 54% bulky disease; 31% ECOG PS 2; 82% elevated LDH
• 55% IPI 3 / aaIPI 2; 43% IPI 4–5 / aaIPI 3
• 8% double/triple hit — a high-risk subgroup included despite R-CHOP being the control
• Broad histologic inclusion: transformed lymphoma, grade 3B FL, T-cell/histiocyte-rich LBCL, EBV+ DLBCL, ALK+ LBCL, HHV8+ DLBCL 
  • Note: On retrospective central review, ~7% of patients had a different histology (roughly half had FL grade 1–3A), underscoring the diagnostic challenges in DLBCL
• ~40% received pre-phase steroids; 8% rituximab; 4% vincristine prior to cycle 1

Key Efficacy Results

(Primary analysis at median follow-up 35.2 months)

 | Endpoint | Tafa-Len-R-CHOP | R-CHOP | HR / p-value | 2-year PFS | 71.1% | 62.9% | HR 0.75, p=0.0194
| 3-year PFS | 67.3% | 60.7% | ~6.6% absolute difference
| Overall Survival | — | — | HR 0.85, p=0.27 (immature)

Points of Discussion:

• Absolute PFS benefit at 2 years: ~8.2%; at 3 years: ~6.6% — a modest but statistically significant improvement
• OS curves cross early, then separate slightly from ~18 months; data remain immature
• Early censoring observed: ~17% (intervention) and ~14% (control) censored by 9 months — raises questions about off-protocol therapy
• Subgroup consistency: PFS benefit appeared consistent across prespecified subgroups; specific subgroups discussed in the episode

Safety

 Adverse Event | Tafa-Len-R-CHOP | R-CHOP 
| Fatal treatment-emergent AEs | 6% (26 pts) | 4% (17 pts)
| Diarrhea (any grade) | 25% | 17%
| Febrile neutropenia | 17% (incl. 1 death) | 13%
| Grade ≥3 anemia | 24% | 17%
| Grade ≥3 thrombocytopenia | 27% | 14%

The addition of tafasitamab and lenalidomide to R-CHOP adds meaningful hematologic toxicity, particularly thrombocytopenia and anemia, as well as diarrhea and febrile neutropenia.

Key Discussion Points from the Episode

1. Did the early-phase L-MIND and First-MIND data justify bringing tafasitamab into the front-line setting, and was tafa-len-R-CHOP the right intervention arm to take forward?
2. Is R-CHOP the appropriate control for a patient population that includes 8% double/triple hit lymphoma?
3. What are the implications of using investigator-assessed PFS as the primary endpoint — and how critical is effective blinding to the integrity of that endpoint?
4. How do we interpret the early OS curve crossing and currently non-significant OS benefit?
5. Is the ~8% absolute PFS improvement at 2 years clinically meaningful enough to change practice — particularly given the added toxicity?
6. How should we think about patient selection: who would you prioritize for tafa-len-R-CHOP over standard R-CHOP in clinical practice?
7. What does frontMIND mean for the DLBCL treatment landscape alongside polatuzumab-R-CHP (POLARIX)?

Resources & Further Reading

• frontMIND trial: Lenz et al. Lancet. https://pubmed.ncbi.nlm.nih.gov/42217458/
• POLARIX: Tilly H, et al. NEJM 2022

About BloodCancerTalks

BloodCancerTalks is a medical education podcast hosted by Raj, Ashwin, and Eddie, dedicated to the latest advances in hematologic malignancies. New episodes available wherever you listen to podcasts.

Follow us on X/Twitter for episode updates and hematology/oncology content.